IDEXX Laboratories, Inc.

Total Valuation

IDEXX Laboratories, Inc. carries a market capitalization of 44.23B, placing it among publicly traded companies globally. Its enterprise value stands at 45.86B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

IDEXX Laboratories, Inc. currently has 79.24M shares outstanding.

Valuation Ratios

IDEXX Laboratories, Inc. trades at a trailing price-to-earnings ratio of 41.05. The price-to-sales ratio is 10.11, and the price-to-book ratio stands at 6.73.

Enterprise Valuation

On an enterprise value basis, IDEXX Laboratories, Inc. trades at an EV/EBITDA multiple of 29.50 and an EV/FCF ratio of 33.48. The EV/Sales ratio of 10.32 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 32.62 provides insight into valuation relative to core operating earnings.

Financial Position

IDEXX Laboratories, Inc. maintains a current ratio of 1.12, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 71.04, indicating elevated leverage, while an interest coverage ratio of 39.94 demonstrates strong ability to service its debt obligations.

Financial Efficiency

IDEXX Laboratories, Inc. posts a return on equity of 17.86 and a return on invested capital of 43.07.

Taxes

Over the trailing twelve months, IDEXX Laboratories, Inc. has paid 274.31M in income taxes, reflecting an effective tax rate of 20.03.

Stock Price Statistics

IDEXX Laboratories, Inc.'s stock has gained approximately 6.8342% over the past 52 weeks. The 50-day moving average sits at 563.82, while the 200-day moving average is 637.25.

Income Statement

Over the trailing twelve months, IDEXX Laboratories, Inc. generated 4.45B in revenue and converted that into 1.10B in net income, yielding earnings per share of 13.59. EBITDA reached 1.55B, while operating income came in at 1.41B.

Balance Sheet

IDEXX Laboratories, Inc. holds 200.53M in cash and equivalents against 1.11B in total debt, resulting in a net debt position of 779.32M. Total book value stands at 6.68B, with working capital of 154.22M providing operational flexibility.

Cash Flow

IDEXX Laboratories, Inc. produced 1.21B in operating cash flow over the past twelve months. After subtracting -128.63M in capital expenditures, free cash flow totaled 1.08B - equivalent to 13.52 per share.

Margins

IDEXX Laboratories, Inc. operates with a gross margin of 62.05, reflecting its pricing power and cost economics. The operating margin of 31.63 and net profit margin of 24.63 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

IDEXX Laboratories, Inc.'s most recent stock split took place on June 16, 2015 with a 1:2 split ratio.

Scores

IDEXX Laboratories, Inc. posts an Altman Z-Score of 21.23, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.